Expert Opinion on Investigational Drugs -Investigational antibody drug conjugates for solid tumors Summary (Pfizer)

Note: access to the full article is payer-per-view ($$$)

"Despite the progress made in the past 20 years in understanding the molecular events leading to the formation of cancer, the success of targeted antitumor agents in solid tumors has lagged behind the scientific discoveries. The most difficult to treat patient segments are those with refractory solid tumors, resistant to standard chemotherapy, and novel therapeutic compounds with improved therapeutic indexes are needed. Antibody drug conjugates (ADCs) are poised to become an important class of cancer therapeutics, as evidenced by the promising objective response rates when administered as single agents to chemorefractory cancer patients..........Herein, we review ADCs (Antibody drug conjugates) targeting solid tumors, with the focus on 11 programs currently undergoing clinical development....)

Pfizer Establishes Rare Disease Research Unit - Pharmaceutical Business Review

Pfizer Inc., 4/9/10 FDA (U.S.) warning letter